Samir Khleif, Georgiamune CEO
Maryland biotech Georgiamune nabs $75M to fund three cancer, autoimmune clinical trials
Maryland biotech Georgiamune emerged Wednesday with a $75 million Series A, clearance to begin its first clinical trial later this year …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
